Clinical Trial Update: Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD [Phase 2]

View source ↗

Summary

Phase 2 safety and preliminary efficacy study of WST11-mediated VTP therapy in CNV associated with AMD was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Stakel (WST11)

Snippet

Sponsor: Steba Biotech S.A. | Conditions: Macular Degeneration, Choroidal Neovascularization | Phase 2 | Status: TERMINATED | Results posted: 2018-09-17